The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for Invokana (canagliflozin; Janssen) to reduce the risk of end-stage renal disease (ESRD) and renal or cardiovascular (CV) death in adults with type 2 diabetes (T2D) and chronic kidney disease (CKD).
Your search for esrd returned 2 results
The ORAL Shift study enrolled 694 RA patients who were inadequate responders to methotrexate alone.
- Loading...
